ArticleEndocrine connections2026
Association between glucagon and stroke in patients with type 2 diabetes.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between fasting glucagon levels and the risk of comorbid stroke in hospitalized patients with type 2 diabetes mellitus (T2DM). Methods: This study included 1,745 T2DM patients hospitalized at Tianjin Medical University General Hospital from September 1, 2022, to September 30, 2025. Patients were divided into a T2DM group and a T2DM with stroke group based on the presence of stroke. Fasting glucagon levels and other clinical data were collected. Binary logistic regression models were used to analyze the relationship between fasting glucagon and stroke risk. Results: Among female T2DM patients, fasting glucagon levels were significantly higher in the T2DM with stroke group compared to the T2DM group (13.38 vs 11.56 pmol/L, P = 0.011). Multivariable logistic regression analysis showed that after adjusting for multiple confounding factors, including age, diabetes duration, BMI, hypertension, eGFR, HbA1c, dyslipidemia, and medication use, higher fasting glucagon levels are independently associated with the presence of comorbid stroke in female T2DM patients (model 3: Q4 vs Q1: OR = 2.396, 95% CI: 1.075-5.339, P = 0.037). In addition, the prevalence of stroke increased with ascending quartiles of glucagon levels in female patients (P = 0.023). However, no significant association was observed between fasting glucagon levels and stroke risk in male patients. Conclusion: This study demonstrates that among hospitalized female patients with T2DM, higher fasting glucagon levels are independently associated with the presence of comorbid stroke. This association suggests a potential link between glucagon and cerebrovascular diseases in this population, warranting further investigation to explore its role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.